Impact on glycated haemoglobin of a biological response-based measure of medication adherence

Diabetes, Obesity and Metabolism

Volumn 17, Issue 9, 2015, Pages 843-848

  Nichols, G A ^a   Rosales, A G ^a   Kimes, T M ^a   Tunceli, K ^b   Kurtyka, K ^b   Mavros, P ^b   Steiner, J F ^c  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Glycaemic control; Metformin; Observational study; Pharmaco epidemiology

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PROPORTION OF DAYS COVERED; TREATMENT OUTCOME; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84939564666     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12476     Document Type: Article

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 2012; 35: 1364-1379.
2. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218-1224.
3. Raebel MA, Schmittdiel J, Karter AJ, Konieczny J, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013; 51: S11-21.
4. Asche C, LaFleur J, Conner CA. Review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011; 33: 74-109.
5. Sacks DB, John WG. Interpretation of hemoglobin A1c values. JAMA 2014; 311: 2271-2272.
6. Adams AS, Trinacty CM, Zhang F et al. Medication adherence and racial differences in A1C control. Diabetes Care 2008; 31: 916-921.
7. Pladevell M, Williams LK, Potts LA, Divine G, Xi H, Elston Lafata J. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004; 27: 2800-2805.
8. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008; 14: 71-75.
9. Bryson CL, Au DH, Young B, McDonnell MB, Fihn SD. A refill adherence algorithm for multiple short intervals to estimate refill complicance (ReComp). Med Care 2007; 45: 497-504.
10. Nagrebetsky A, Griffin S, Kinmonth AL, Sutton S, Craven A, Farmer A. Predictors of suboptimal glycaemic control in type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. Diabetes Res Clin Pract 2012; 96: 119-128.
11. Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010; 26: 2127-2135.
12. Schmittdiel JA, Nichols GA, Dyer W, Steiner JF, Karter AJ, Raebel MA. Medicare STAR excludes diabetes patients with poor CVD risk factor control. Am J Manag Care 2014; 20: e581-e589.
13. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 2009; 44: 1640-1661.
14. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
15. Cefalu WT, Buse JB, Del Prato S et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' forum. Diabetes Care 2014; 37: 2647-2659.